< Key Hightlight >

The global ATP assays market is projected to reach USD 412 million by 2027 from USD 276 million in 2022, at a CAGR of 8.4%. The growth of this market can largely be attributed to the increasing food safety concerns, growing demand for ATP assays in pharmaceutical & biotechnology companies, rising investments in pharmaceutical & biotechnology R&D, increasing prevalence of cancer and other chronic and infectious diseases, and the shift from culture-based tests to rapid tests. However, the high cost of instruments and inability to differentiate between extracellular and intracellular ATP are expected to restrain the growth of this market to a certain extent. 

“The consumables and accessories segment accounted for the largest share of the ATP assays, based on  product in 2021.”

Based on products, the ATP assays market is segmented into consumables & accessories and instruments. The large share of consumables & accessories segment is attributed to the extensive usage of ATP assays in research institutes to measure cell viability, increase in drug discovery due to a surge in chronic diseases which requires tumor testing and cell proliferation (in cancer), and the repeated purchase of consumables by pharmaceutical and biotechnology companies. 

“Contamination Testing accounted for the largest share of the market.”

The ATP assays market is segmented into contamination testing, disease testing, and drug discovery & development. The large share of the contamination testing segment can be attributed to the rising regulatory stringency of pharmaceutical and food & beverage companies for non-contaminated production, an increase in drug discovery post COVID-19, and the need for cleaning and disinfection of environmental surfaces in hospitals.

“Pharmaceutical & Biotechnology companies hold the largest share in the market, by end user”

The large share of Pharmaceutical & Biotechnology companies in the end user segment can be attributed to the presence of a large number of pharmaceutical players with growing investments in this market, growing regulatory approvals for cell culture-based vaccines which require the use of ATP assays in contamination testing, commercial expansion of various pharmaceutical companies, the increasing demand for cell and gene therapies for chronic diseases, significant R&D in pharmaceutical & biopharmaceutical companies, increasing production of COVID-19 drugs, increasing adoption of cell-based assays for drug development, and the ease of use of ATP assays in contamination testing.

“The APAC to witness the highest growth during the forecast period.”

Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2022–2027. This regional market is expected to register the highest growth rate during the forecast period as several APAC countries are witnessing a growing number of proteomics, genomics, and stem cell research activities. The increasing incidence of chronic & infectious diseases, increasing drug discovery & development studies, favorable regulatory guidelines,  the growing focus of global market players on emerging Asian economies, increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and research infrastructure modernization are some of the key factors driving the market for ATP assays. 

Break of primary participants was as mentioned below:

• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%

• By Designation – C-level–35%, Director-level–25%, Others–40%

• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the ATP Assays Market

The prominent players in the ATP assays market are Thermo Fisher Scientific, Inc. (US), Promega Corporation (US), Merck KGaA (Germany), PerkinElmer, Inc. (US), Agilent Technologies, Inc. (US), Abcam plc (UK), Lonza Group (Switzerland), NEOGEN Corporation (US), 3M (US), Danaher Corporation (US), PromoCell GmbH (Germany), Geno Technology, Inc. (US), Abnova Corporation (Taiwan), AAT Bioquest (US), BioThema AB (Sweden), Elabscience Biotechnology Inc. (US), MBL International Corporation (US), Biotium (US), Creative Bioarray (US), Canvax Biotech S.L. (Spain), Ruhof Corporation (US), Charm Sciences, Inc. (US), Bio Shield Tech LLC (US), Cayman Chemical (US), and Cell Signaling Technology (US).

Research Coverage:

The report analyzes the ATP assays market and aims at estimating the market size and future growth potential of this market based on various segments such as product, application, end user, and region. The report also includes a product portfolio matrix of various ATP assays products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies. 

Reasons to Buy the Report 

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

• Market Penetration: Comprehensive information on product portfolios offered by the top players in the ATP assays market. The report analyzes this market by product, by application, and  by end user.

• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global ATP assays market

• Market Development: Comprehensive information on the lucrative emerging markets by product, application, and end user

• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global ATP assays market

• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global ATP assays market.